bluuebunny/crossref_metadata_2025_split huggingface dataset:
Roman Imperialism
Authors: Burton Paul J. 
Published: April 2019

Abstract
Rome engaged in military and diplomatic expansionistic state behavior, which we now describe as ‘imperialism,’ since well before the appearance of ancient sources describing this activity. Over the course of at least 800 years, the Romans established and maintained a Mediterranean-wide empire from Spain to Syria (and sometimes farther east) and from the North Sea to North Africa. How and why they did this is a source of perennial scholarly controversy. Earlier debates over whether Rome was an aggressive or defensive imperial state have progressed to theoretically informed discussions of the extent to which system-level or discursive pressures shaped the Roman Empire. Roman imperialism studies now encompass such ancillary subfields as Roman frontier studies and Romanization.
Putative biomarkers of malignant transformation of sinonasal inverted papilloma into squamous cell carcinoma
Authors: Yang Zheng , Zhang Yang , Wang Xiangdong , Huang Junwei , Guo Wei , Wei Peng , Li Guojun , Wang Ziqiao , Huang Zhigang , Zhang Luo 
Published: April 2019

Objective To compare genome-wide DNA methylation between samples of sinonasal inverted papilloma (SNIP) and squamous cell carcinoma (SCC) samples in order to identify aberrantly methylated genes that might be involved in malignant transformation. Methods Tissue samples were collected from patients. DNA methylation in C-phosphate-G islands and gene promoters was analysed using a DNA methylation microarray kit. The levels of mRNA or protein from aberrantly methylated genes were measured using real-time polymerase chain reaction or Western blot analysis. Results A total of 27 tissue samples were included in this study; 15 SNIP samples and 12 SCCs arising in SNIPs. A total of 11 201 nominally differentially methylated sites were observed between SNIP and SCC arising in SNIPs. Six sites were significantly different at P < 0.01 and contained three genes ( MIR661, PLEC and OPA3). These three genes were hypermethylated. In addition, the levels of mature miR-661 mRNA and PLEC protein were significantly upregulated in SCC tissues compared with SNIP samples. The levels of OPA3 protein were downregulated in SCC tissues compared with SNIP samples. Conclusions This study demonstrated hypermethylation and abnormal expression of the MIR661, PLEC and OPA3 genes, suggesting a role for their involvement in the malignant transformation of SNIP.
Usher syndrome in a patient with Ellis–van Creveld syndrome
Authors: Romano Francesco , Albertini Giorgia Carlotta , Arrigo Alessandro , Leone Pier Pasquale , Bandello Francesco , Battaglia Parodi Maurizio 
Published: April 2019

Purpose: To describe a case of Ellis–van Creveld syndrome with concomitant Usher syndrome. Methods: A 24-year-old lady with a diagnosis of Ellis–van Creveld syndrome came to our attention in 2015 complaining of nyctalopia. She underwent yearly ophthalmologic examinations, including visual acuity, dilated fundoscopy, optical coherence tomography and colour fundus photography. Results: On the day of her first examination, her visual acuity was 20/20, whereas fundus examination revealed diffuse peripheral retinal atrophy with pigmented bone spicules, waxy pallor of the disc and macular sparing in both eyes, compatible with retinitis pigmentosa. Due to the severe retinitis pigmentosa phenotype for the age and the concomitant neurosensory hearing loss, ancillary electrophysiological and genetic tests were requested. At the end of follow-up, visual function remained stable, with electroretinogram tests confirming the peripheral dysfunction. Interestingly, next generation sequencing test revealed a mutation in USH2A gene, suggestive of an overlapping Usher syndrome. On optical coherence tomography angiography, all plexuses appeared altered, with some degree of impairment also in the choriocapillaris of the spared macula. Conclusion: Our report emphasizes the advantage of new genetic tests to investigate atypical presentations of known retinal disorders found in syndromic settings. In addition, we speculate that the underlying ciliopathy might possibly aggravate the phenotype of this case of Usher syndrome.
Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis
Authors: Phung Michelle , Ighani Arvin , Georgakopoulos Jorge R , Vender Ron , Giroux Lyne , Lansang Perla , Yeung Jensen 
Published: April 2019

Background: Secukinumab is an anti-IL-17A monoclonal antibody approved for the treatment of moderate-to-severe psoriasis in adult patients. Despite its favourable safety and efficacy profile in clinical trials, some patients in clinical practice fail to respond adequately to the approved maintenance regimen of 300 mg subcutaneous monthly. Some clinicians manage these patients by using off-label high-dose secukinumab regimens, which include shortening the dosing interval to 300 mg every 2 or 3 weeks instead of monthly, or increasing the monthly dose to 450 mg. Objective: This study aims to investigate the safety and efficacy of high-dose secukinumab regimens for the treatment of psoriasis to inform real-world clinical practice. Methods: We performed a retrospective chart review at 5 dermatology clinics for adult patients diagnosed with moderate-to-severe psoriasis treated with an off-label high-dose secukinumab regimen. Efficacy was measured using the Psoriasis Area and Severity Index or a Physician Global Assessment score of 0 or 1 after dose escalation. Adverse events were recorded to assess safety outcomes. Results: Twenty-five patients were included in this case series, and 14 of them achieved efficacy from dose escalation with secukinumab based on our study endpoints. There was 1 case of the common cold and 1 upper respiratory tract infection reported after dose escalation. Conclusion: Our study provides evidence that dose escalation with secukinumab results in clinical benefit and is well tolerated among patients with moderate-to-severe psoriasis who failed to respond adequately to the approved regimen. This work necessitates larger studies to fully characterize the efficacy and long-term safety profile of secukinumab dose escalation.
Predictors of Student Engagement in Learning Communities
Authors: Baños James H , Noah Jason P , Harada Caroline N 
Published: April 2019

Introduction: Little is known about what factors predict student engagement in learning communities (LCs). At our institution, we recently converted from an informal, unfunded program with volunteer mentors and no participation requirement to a formal, funded program with a structured curriculum, dedicated mentors, and required attendance. We sought to identify factors that predict student engagement in this new program. Methods: Medical students from all 4 years were invited to complete a survey that included self-rating of their level of engagement with their LC. We hypothesized that student engagement would be (1) higher in the new, formal program compared with the informal program; (2) lower among older students; and (3) higher among students who value collective activities for stress management. Results: In total, 75% of students completed the survey. Students who participated in the formal LC program reported significantly higher engagement than those who experienced the informal version. Older, out-of-state, and underrepresented in medicine (URiM) students reported lower levels of engagement compared with younger, in-state, and non-URiM students, but gender and campus assignment were not associated with level of engagement. Students who valued participation in extracurricular activities, service work, and time with friends or family all had higher levels of engagement in LCs compared with those who valued more solitary activities. Discussion: The formal, structured LC program was associated with higher levels of engagement than the informal program, and engagement was maintained throughout the 4-year curriculum. Subgroups of students reported lower engagement in LCs, and future research is needed to better understand and address this variability in engagement. This study is limited by the fact that students are only surveyed once annually, at a single institution, and our measure of engagement is brief and dependent on student self-report. In addition, it is not possible to discern from this study which components of the formal LC program were most strongly associated with high engagement.
Collaborative diagnosis between clinician and patient: why to do it and what to consider
Authors: Hackmann Corinna , Wilson Jon , Perkins Amorette , Zeilig Hannah 
Published: April 2019

SUMMARYThis article discusses findings from the literature and our own research related to the experience of the diagnostic process in mental healthcare, primarily from the perspective of patients, and it focuses on the benefits of collaboration. A common finding throughout our research is that, if a diagnostic process is undertaken, the majority of patients want to be actively involved and feel valued in it. This helps ensure that they find the process and the resulting diagnosis to be meaningful, informative and useful. We believe that collaboration could also mitigate some of the reported negative unintended consequences of diagnosis, including feeling stigmatised, labelled and disempowered. Our work has led us to conceive of diagnosis as having two overarching elements: the diagnostic process and the resulting diagnostic label. This article focuses specifically on the diagnostic process; we do not consider here the debate surrounding the evidence base for the validity of psychiatric classification.LEARNING OBJECTIVESAfter reading this article you will be able to:
•understand patients' experiences of the diagnostic process•achieve a shared and collaborative diagnostic process with patients•reflect on potential barriers and facilitators to collaborative diagnosis in your own practice.DECLARATION OF INTERESTNone.
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Authors: Sharman Jeff P. , Coutre Steven E. , Furman Richard R. , Cheson Bruce D. , Pagel John M. , Hillmen Peter , Barrientos Jacqueline C. , Zelenetz Andrew D. , Kipps Thomas J. , Flinn Ian W. , Ghia Paolo , Eradat Herbert , Ervin Thomas , Lamanna Nicole , Coiffier Bertrand , Pettitt Andrew R. , Ma Shuo , Tausch Eugen , Cramer Paula , Huang Julie , Mitra Siddhartha , Hallek Michael , O’Brien Susan M. , Stilgenbauer Stephan 
Published: April 2019

PURPOSE A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab versus placebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was terminated early because of superior efficacy of the IDELA-plus-rituximab (IDELA/R) arm. Patients in either arm could then enroll in an extension study to receive IDELA monotherapy. Here, we report the long-term efficacy and safety data for IDELA-treated patients across the primary and extension studies. PATIENTS AND METHODS Patients were randomly assigned to receive rituximab in combination with either IDELA 150 mg twice daily (IDELA/R; n = 110) or placebo (placebo/R; n = 110). Key end points were progression-free survival (PFS), overall response rate (ORR), overall survival (OS), and safety. RESULTS The long-term efficacy and safety of treatment with IDELA was assessed in 110 patients who received at least one dose of IDELA in the primary study, 75 of whom enrolled in the extension study. The IDELA/R-to-IDELA group had a median PFS of 20.3 months (95% CI, 17.3 to 26.3 months) after a median follow-up time of 18 months (range, 0.3 to 67.6 months). The ORR was 85.5% (94 of 110 patients; n = 1 complete response). The median OS was 40.6 months (95% CI, 28.5 to 57.3 months) and 34.6 months (95% CI, 16.0 months to not reached) for patients randomly assigned to the IDELA/R and placebo/R groups, respectively. Prolonged exposure to IDELA increased the incidence of all-grade, grade 2, and grade 3 or greater diarrhea (46.4%, 17.3%, and 16.4%, respectively), all-grade and grade 3 or greater colitis (10.9% and 8.2%, respectively) and all-grade and grade 3 or greater pneumonitis (10.0% and 6.4%, respectively) but did not increase the incidence of elevated hepatic aminotransferases. CONCLUSION IDELA improved PFS and OS compared with rituximab alone in patients with relapsed CLL. Long-term IDELA was effective and had an expected safety profile. No new IDELA-related adverse events were identified with longer exposure.
Vergence eye movements in bipolar disorder
Authors: Chrobak Adrian , Rybakowski Janusz , Abramowicz Maria , Perdziak Maciej , Gryncewicz Wojciech , Tereszko Anna , Włodarczyk Marta , Dziuda Sebastian , Fafrowicz Magdalena , Czarnecki Paweł , Sołtys Zbigniew , Siwek Marcin , Ober Jan , Marek Tadeusz , Dudek Dominika 
Published: April 2019

Cel pracyW odniesieniu do choroby afektywnej dwubiegunowej (ChAD), dotychczasowe prace wskazują na zaburzenia ruchów sakadycznych, głównie pod postacią wydłużenia czasu reakcji (latencji) w testach prosakad i antysakad. Dotychczas nie przeprowadzono oceny ruchów wergencyjnych gałek ocznych u osób z ChAD. Głównym celem naszego badania jest ocena parametrów konwergencji (zbieżne ruchy gałek ocznych) w tej grupie klinicznej.MetodaDo badania włączono 30 pacjentów z ChAD w stanie remisji objawowej i 23 zdrowych ochotników. Uczestników poddano badaniu optometrycznemu oceniającemu punkt bliski konwergencji przy użyciu pręta fiksacyjnego. Badanie okulometryczne przeprowadzono przy pomocy okulografu wykorzystującego promieniowanie podczerwone z dedykowanym stymulatorem wergencji.WynikiPacjenci z ChAD wykazali istotnie większy średni błąd pozycji konwergencji do celu oraz większą liczbę wtrąceń sakadycznych w porównaniu do grupy kontrolnej. Analiza składowych głównych przeprowadzona na zmiennych okulometrycznych pokazała istotne różnice między pacjentami z ChAD a zdrowymi ochotnikami. Wykazano obecność istotnych korelacji między zaburzeniami ruchów wergencyjnych a liczbą wtrąceń sakadycznych.WnioskiPacjenci z ChAD ujawnili zaburzenia ruchów wergencyjnych gałek ocznych podobne do zaburzeń opisywanych w trakcie śledzenia bodźców poruszających się w płaszczyźnie czołowej. Podczas gdy zaburzenia wergencji były opisywane w innych zaburzeniach psychicznych, nasza praca po raz pierwszy obiektywnie zmierzyła to zjawisko w ChAD.
Direct Estimation of HDL-Mediated Cholesterol Efflux Capacity from Serum
Authors: Kuusisto Sanna , Holmes Michael V , Ohukainen Pauli , Kangas Antti J , Karsikas Mari , Tiainen Mika , Perola Markus , Salomaa Veikko , Kettunen Johannes , Ala-Korpela Mika 
Published: April 2019

Abstract

BACKGROUND
HDL-mediated cholesterol efflux capacity (HDL-CEC) is a functional attribute that may have a protective role in atherogenesis. However, the estimation of HDL-CEC is based on in vitro cell assays that are laborious and hamper large-scale phenotyping.

METHODS
Here, we present a cost-effective high-throughput nuclear magnetic resonance (NMR) spectroscopy method to estimate HDL-CEC directly from serum. We applied the new method in a population-based study of 7603 individuals including 574 who developed incident coronary heart disease (CHD) during 15 years of follow-up, making this the largest quantitative study for HDL-CEC.

RESULTS
As estimated by NMR-spectroscopy, a 1-SD higher HDL-CEC was associated with a lower risk of incident CHD (hazards ratio, 0.86; 95%CI, 0.79–0.93, adjusted for traditional risk factors and HDL-C). These findings are consistent with published associations based on in vitro cell assays.

CONCLUSIONS
These corroborative large-scale findings provide further support for a potential protective role of HDL-CEC in CHD and substantiate this new method and its future applications.
Optimization and Comparison of Information-Dependent Acquisition (IDA) to Sequential Window Acquisition of All Theoretical Fragment Ion Spectra (SWATH) for High-Resolution Mass Spectrometry in Clinical Toxicology
Authors: Whitman Jeffrey D , Lynch Kara L 
Published: April 2019

Abstract

BACKGROUND
Untargeted data acquisition on high-resolution mass spectrometers (HRMSs) has been used in clinical toxicology for screening and identifying unknown compounds in patient samples. A common modality for untargeted HRMS data acquisition is information-dependent acquisition (IDA), which analyzes the most abundant small molecules within an acquisition cycle. This process can potentially lead to false negatives of clinically relevant compounds at low concentrations. Sequential window acquisition of all theoretical fragment ion spectra (SWATH) has emerged as a method of unbiased, untargeted HRMS data acquisition in which no spectral data are lost. SWATH has yet to be optimized and assessed for use in clinical toxicology.

METHOD
We developed a variable-window SWATH method (vSWATH) and compared it to IDA by limit of detection studies in drug-supplemented urine (81 compounds) and against a retrospective cohort of 50 clinical urine samples characterized by LC-MS/MS.

RESULTS
vSWATH had a lower limit of detection than IDA for 33 (41%) drugs and metabolites added into urine samples. Both IDA and vSWATH were equivalent in discovering compounds from clinical urine samples and confirmed 26 additional compounds not previously discovered by targeted LC-MS/MS. Lastly, the unbiased acquisition of spectra in vSWATH allowed for identification of 5 low-abundance compounds missed by IDA.

CONCLUSIONS
This vSWATH method for clinical toxicology demonstrated equivalent analytical sensitivity and specificity for untargeted drug screening and identification in urine samples. vSWATH provided the additional benefit of collecting all tandem mass spectrometry spectra in a sample, which could be useful in discovering low-abundance compounds not discovered by IDA.
ДОКУМЕНТНАЯ КОММУНИКАЦИЯ В КОНТЕКСТЕ ЛИНГВИСТИЧЕСКОЙ ЭКСПЕРТИЗЫ
Authors: Kushnir Olga , Martyshev Ivan 
Published: April 2019

В статье рассматривается проблема, находящаяся на стыке документоведения, лингвистики и юриспруденции, − проблема качества текстов официальных документов, прежде всего − документов, обладающих юридической силой. Классификация документов на официальные и иные проводится на основании свойства документа воздействовать на правоотношения, или иметь юридическую силу. Применяемое в документоведении понятие «юридическая значимость документа» применимо как к официальным, так и к иным документам. По мнению авторов, принципиальным различием между указанными свойствами документов является временнáя соотнесенность самих процессов: возникновение документа и возникновение события или действия, с которым документ связан юридической силой или юридической значимостью: юридическая сила связывает документ с событиями или действиями, которые наступают, как правило, после издания документа, а юридическая значимость связывает документ с произошедшими событиями / совершенными действиями. Грань между двумя процессами, вызывающими проявление указанных свойств документа, весьма зыбкая. При этом один документ может обладать одновременно и юридической силой, и юридической значимостью. Предметом лингвистической экспертизы чаще всего становятся тексты официальных документов, которые обладают юридической силой, поскольку их собственно правовая и социальная значимость выше, чем у всех других документов. Но и само свойство юридической силы у разных видов документов различно и зависит от правового статуса и компетенции автора (авторов) документа и от его функционального назначения. В практике лингвистической экспертизы документных текстов различают экспертизу, проводимую на стадии проектирования текста документа, и экспертизу, проводимую на стадии его применения: в первом случае проявляется превентивная функция лингвистической экспертизы, во втором – детективная. Лингвистическая экспертиза документных текстов, по заключению авторов, должна получить четкий институциональный статус в документной коммуникации и в системе государственного и муниципального управления, и на корпоративном (локальном) уровне.
Comparison of the effect of vitamin D on osteoporosis and osteoporotic patients with healthy individuals referred to the Bone Density Measurement Center
Authors: Shahnazari Banafsheh , Moghimi Jamileh , Foroutan Majid , Mirmohammadkhani Majid , Ghorbani Amir 
Published: April 2019

AbstractObjectiveOsteoporosis is the most common metabolic disease of the bones. Osteoporosis reduces bone density, predisposes a person to fractures, and imposes high costs on societies. Osteoporosis develops from a variety of causes, one of the most significant is vitamin D deficiency. This study investigates the impact of vitamin D on osteoporosis.Materials and MethodsIn this clinical trial, 400 patients referred to the Bone Density Clinic of Kowsar Hospital in Semnan were selected by convenience sampling method. Bone densitometry tests were carried out using DEXA (x-ray absorptiometry) and serum vitamin D levels were measured by the ELISA method. Subjects with vitamin D deficiency were treated for 8 weeks with (50,000 Vitamin D units per week. At the end of the treatment period, all subjects were evaluated for bone density and the results of both groups were compared.Results13% of subjects had osteoporosis and 14.2% had osteopenia. 19% of subjects had vitamin D deficiency, 38.8% had insufficient levels of vitamin D, and 42.3% had sufficient vitamin D levels. The level of vitamin D in patients with osteoporosis (5.50 ± 5.5 ng/ml) was less than those with osteopenia (7.83 ± 4.8 ng/ml) and those with normal bone mineral density (23.88 ± 18.42 ng/ml) (P <0.001). The prevalence of osteoporosis in the intervention group after intervention with vitamin D was significantly lower than the control group (32.3 versus 67.7 and P <0.001).ConclusionThe prevalence of serum vitamin D deficiency in osteopenic and osteoporotic individuals was higher than in normal subjects, with a significant relationship between age and sex. Thus, treatment with vitamin D improves bone density indices.
Jatropha seed oil derived poly(esteramide-urethane)/ fumed silica nanocomposite coatings for corrosion protection
Authors: Alam Manawwer , Alandis Naser M , Ahmad Naushad , Alam Mohammad Asif , Sharmin Eram 
Published: April 2019

AbstractJatropha oil [JO] based poly (esteramide-urethane) coatings embedded with fumed silica nanoparticles were prepared. JO was converted to N,N-bis(2-hydroxy ethyl) JO fatty amide (HEJA) and was further modified by a tetrafunctional carboxylic acid(trans1,2 diaminocyclo-hexane-N,N,N’,N’,-tetraacetic acid) to form poly (diamino cyclohexane esteramide) (PDCEA). PDCEA was then treated with toluene 2,4-diisocynate and fumed silica to prepare poly(diamino cyclohexane urethane esteramide) (PUDCEA) nanocomposite. The formation of PDCEA and PUDCEA nanocomposites was confirmed by FTIR,1H &13C NMR spectroscopic techniques. The thermal behavior and morphology of PUDCEA nanocomposite coatings were investigated by TGA/DTG, DSC, SEM, EDX spectroscopy. PUDCEA nanocomposites were applied on carbon steel and their coatings were produced at room temperature. The properties of these nanocomposite coatings were investigated by standard analytical methods. The PUDCEA-3 nanocomposite showed good anticorrosion and physico-mechanical performance. These naocomposite coatings can be employed safely upto 200oC.